Comment from Combination Products Coalition

Summary: The Combination Products Coalition (CPC), representing drug, biological, and medical device manufacturers, supports the FDA's guidance but proposes specific revisions to clarify regulatory boundaries. They argue for clearer exemptions for patient-facing software, more flexible interpretations of "clinically appropriate" and "time-critical" criteria, and the inclusion of AI/ML-specific validation methods to reduce regulatory burden and promote innovation.